## 1 Introduction  
Current approaches to regenerate the entire IVD or parts of IVDs are not very successful. Lower back pain (LBP) is a dominant medical problem that affects billions of people worldwide, yet no cure is in close sight. Orthopedic surgery often removes the affected motional segment by so-called \"discectomy\" and tries to fuse the two adjacent segments to achieve stability, possibly removing the LBP. However, tissue-engineered solutions have been developed to target a biological and, hopefully, more physiological solution to the problem. This Special Issue provides a cross-disciplinary section of \"applied science\" in this field of biomedical research ranging from biomechanics [1], biomaterials such as hyaluronic acid (HA) [2], and cell physiology [3] to in vitro cell culture studies on how cell phenotypes should be directed towards more IVD-like cells [4; 5; 6]. Traditionally, three tissue types are distinguished of the IVD, i.e., the nucleus pulposus (NP), the annulus fibrosus (AF), and the cartilaginous endplates (CEP) [7]. Thus, the articles partially focus on the generation of in vitro NP cells and how to provide a micro-environment for these [2]. In addition, an innovative approach is presented regarding how Angiotensin II Type 1 Receptor Antagonist \"Losartanon\" could be used to partially reverse inflammation caused by tumor necrosis factor alpha (TNF\(\alpha\)) [4]. 2 Highlights on the Studies Published in the Present Special Issue: Intervertebral Disc Regeneration  
The first highlight to mention is the valuable contribution of the group of Prof. [PERSON] and his team on how the process of lumbar disc herniation can be provoked using in vitro biomechanical testing protocols [1]. [PERSON] et al. (1999) [8] provided essential knowledge on the in vivo physiological loading patterns in human IVDs following the first observations by [PERSON] [9] in 1966. In this Special Issue for the first time, a successful loading regime is presented that can reproduce the herniation of NP material from the inner part of the IVD as in the clinical situation [1]. Furthermore, two excellent reviews are presented in this Special Issue: one is on the usage of HA for the application of IVD regeneration by the group of Prof. [PERSON] [2]. This group is extremely knowledgeable on various aspects of biomaterials for multiple applications in musculoskeletal regeneration and provides an excellent review of the studies involving HA for IVD repair. The second review focuses on progress using many allogeneic progenitor cells for cell therapy in ongoing clinical trials by Prof. [PERSON] and his team [10]. Furthermore, two studies were published by Prof. [PERSON] and his team around progenitor cells [5,6]. One manuscript by [PERSON] et al. (2021) [5] reports an exciting approach how NPPCs can be better kept in culture using specialized spheroid culture systems. The second study by the same laboratory team then reports on in vitro screening for the most suitable combination of cytokines to differentiate MSCs towards NP-like cells [6]. This discussion on how to obtain NP-like cells from progenitors, of course, already began much earlier and can be read in more detail in many other articles presented by other research groups, e.g., [11, 12, 13]. It was exciting to learn that a combination of growth and differentiation factor 5 (GDF5) and transforming growth factor beta 1 (TGF1) was the most promising combination towards an NP-like phenotype. The author wishes to acknowledge his current funding sources: This research was enabled by the Swiss National Science Foundation project #31003E_192674/1 ([[https://p3.snf.ch/project-19](https://p3.snf.ch/project-19)]([https://p3.snf.ch/project-19](https://p3.snf.ch/project-19)) 2674, accessed on 1 December 2021).